APA (7th ed.) Citation

A, B., Y, F., AY, K., JZ, L., LR, B., S, J., . . . RT, G. (2026). 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 81(Supplement_3), i6. https://doi.org/10.1093/cid/ciae435

Chicago Style (17th ed.) Citation

A, Bhimraj, et al. "2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 81, no. Supplement_3 (2026): i6. https://doi.org/10.1093/cid/ciae435.

MLA (9th ed.) Citation

A, Bhimraj, et al. "2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 81, no. Supplement_3, 2026, p. i6, https://doi.org/10.1093/cid/ciae435.